Влияние клинических характеристик и объема циторедукции у больных с первичной глиобластомой на выживаемость свыше 3-х лет

Standard

Влияние клинических характеристик и объема циторедукции у больных с первичной глиобластомой на выживаемость свыше 3-х лет. / Matsko, M. V.; Matsko, D. E.; Volkov, N. M.; Ulitin, A. Yu; Lyevleva, A. G.

в: Вопросы онкологии, Том 63, № 6, 2017, стр. 907-914.

Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование

BibTeX

@article{50cdfe1e8a884baca839d15fcf656bf9,

title = "Влияние клинических характеристик и объема циторедукции у больных с первичной глиобластомой на выживаемость свыше 3-х лет",

abstract = "Patients with glioblastoma (GB) rarely survive more than 3 years. This study aimed to analyze clinical characteristics! of long-term GB survivors. 69 patients with primary GB who were treated at the A.L. Polenov Neurosurgical Institute since 2009 and had sufficient follow-up were analyzed; survival of 11 of these patients exceeded 3 years, while the remaining ;58 failed to achieve this threshold. An immunohistochemi- I cal study was performed using Ki-67 and GFAP antibodies. i Patients were divided into two groups: the first included 11 patients with a survival rate of more than 3 years, the second f (comparison group) with a survival rate of less than 3 years included 58 patients. Long-term survival correlated with the younger patients age (p = 0.002) and tumor response to temo-zolomide (p = 0.004). Other clinical features, including gender (p = 0.484), Karnovsky status (p = 0.322); tumor location (p = 0.078), volume of the lesion and the number of affected lobes (p = 0.132), the number of surgical interventions (p = 0.278) and the volume of cytoreduction (p = 0.105) were not prognostic in this small patient cohort.",

keywords = "Glioblastoma, Prognostic factors, Survival",

author = "Matsko, {M. V.} and Matsko, {D. E.} and Volkov, {N. M.} and Ulitin, {A. Yu} and Lyevleva, {A. G.}",

year = "2017",

language = "русский",

volume = "63",

pages = "907--914",

journal = "Вопросы онкологии",

issn = "0507-3758",

publisher = "Медицина",

number = "6",

}

RIS

TY - JOUR

T1 - Влияние клинических характеристик и объема циторедукции у больных с первичной глиобластомой на выживаемость свыше 3-х лет

AU - Matsko, M. V.

AU - Matsko, D. E.

AU - Volkov, N. M.

AU - Ulitin, A. Yu

AU - Lyevleva, A. G.

PY - 2017

Y1 - 2017

N2 - Patients with glioblastoma (GB) rarely survive more than 3 years. This study aimed to analyze clinical characteristics! of long-term GB survivors. 69 patients with primary GB who were treated at the A.L. Polenov Neurosurgical Institute since 2009 and had sufficient follow-up were analyzed; survival of 11 of these patients exceeded 3 years, while the remaining ;58 failed to achieve this threshold. An immunohistochemi- I cal study was performed using Ki-67 and GFAP antibodies. i Patients were divided into two groups: the first included 11 patients with a survival rate of more than 3 years, the second f (comparison group) with a survival rate of less than 3 years included 58 patients. Long-term survival correlated with the younger patients age (p = 0.002) and tumor response to temo-zolomide (p = 0.004). Other clinical features, including gender (p = 0.484), Karnovsky status (p = 0.322); tumor location (p = 0.078), volume of the lesion and the number of affected lobes (p = 0.132), the number of surgical interventions (p = 0.278) and the volume of cytoreduction (p = 0.105) were not prognostic in this small patient cohort.

AB - Patients with glioblastoma (GB) rarely survive more than 3 years. This study aimed to analyze clinical characteristics! of long-term GB survivors. 69 patients with primary GB who were treated at the A.L. Polenov Neurosurgical Institute since 2009 and had sufficient follow-up were analyzed; survival of 11 of these patients exceeded 3 years, while the remaining ;58 failed to achieve this threshold. An immunohistochemi- I cal study was performed using Ki-67 and GFAP antibodies. i Patients were divided into two groups: the first included 11 patients with a survival rate of more than 3 years, the second f (comparison group) with a survival rate of less than 3 years included 58 patients. Long-term survival correlated with the younger patients age (p = 0.002) and tumor response to temo-zolomide (p = 0.004). Other clinical features, including gender (p = 0.484), Karnovsky status (p = 0.322); tumor location (p = 0.078), volume of the lesion and the number of affected lobes (p = 0.132), the number of surgical interventions (p = 0.278) and the volume of cytoreduction (p = 0.105) were not prognostic in this small patient cohort.

KW - Glioblastoma

KW - Prognostic factors

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85044173299&partnerID=8YFLogxK

M3 - статья

AN - SCOPUS:85044173299

VL - 63

SP - 907

EP - 914

JO - Вопросы онкологии

JF - Вопросы онкологии

SN - 0507-3758

IS - 6

ER -

ID: 39064471